Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-quinolinyl-pentanamides as selective dopamine D3 receptor ligands

被引:0
|
作者
Blass, Benjamin E. [1 ]
Chen, Peng-Jen [1 ]
Taylor, Michelle [2 ]
Griffin, Suzy A. [2 ]
Gordon, John C. [1 ]
Luedtke, Robert R. [2 ]
机构
[1] Temple Univ, Dept Pharmaceut Sci, Sch Pharm, 3307 North Broad St, Philadelphia, PA 19122 USA
[2] Univ North Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA
基金
美国国家卫生研究院;
关键词
Dopamine; D-3 dopamine receptor; D-2 dopamine receptor;
D O I
10.1007/s00044-022-02873-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dopamine (1) plays a key role in normal physiological pathways in both the central nervous system and the periphery. The physiological impact of this neurotransmitter is mediated through its interaction with family of G-protein-coupled receptors (GPCRs). These receptors are designated as D-1, D-2, D-3, D-4, and D-5 and divided into two sub-families, the D-1-like sub-family (D-1 and D-5) and D-2-like sub-family (D-2, D-3 and D-4) based on pharmacological properties, amino acid homology, and genetic organization. Aberrant D-3 activity has been linked to multiple diseases and conditions such as depression, schizophrenia, substance use disorder, inflammatory diseases, and Parkinson's disease (PD). As part of our on-going program focused on the identification of novel D-3 ligands, we have identified a novel series of 5-(4-arylpiperazin-1-yl)-N-quinolinyl-pentanamides that are high affinity ligands for this receptor. [GRAPHICS] .
引用
收藏
页码:749 / 761
页数:13
相关论文
共 50 条
  • [1] Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-quinolinyl-pentanamides as selective dopamine D3 receptor ligands
    Benjamin E. Blass
    Peng-Jen Chen
    Michelle Taylor
    Suzy A. Griffin
    John C. Gordon
    Robert R. Luedtke
    Medicinal Chemistry Research, 2022, 31 : 749 - 761
  • [2] Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides as selective dopamine D3 receptor ligands
    Blass, Benjamin E.
    Chen, Peng-Jen
    Taylor, Michelle
    Griffin, Suzy A.
    Gordon, John C.
    Luedtke, Robert R.
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (01) : 132 - 145
  • [3] Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides as selective dopamine D3 receptor ligands
    Benjamin E. Blass
    Peng-Jen Chen
    Michelle Taylor
    Suzy A. Griffin
    John C. Gordon
    Robert R. Luedtke
    Medicinal Chemistry Research, 2022, 31 : 132 - 145
  • [4] Synthesis of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides and their evaluation as D3 receptor ligands
    Benjamin E. Blass
    Peng-Jen Chen
    John C. Gordon
    Medicinal Chemistry Research, 2022, 31 : 735 - 748
  • [5] Synthesis of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides and their evaluation as D-3 receptor ligands
    Blass, Benjamin E.
    Chen, Peng-Jen
    Gordon, John C.
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (05) : 735 - 748
  • [6] Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 receptor Ligands
    Leopoldo, M
    Berardi, F
    Colabufo, NA
    De Giorgio, P
    Lacivita, E
    Perrone, R
    Tortorella, V
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (26) : 5727 - 5735
  • [7] Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands
    Leopoldo, M
    Lacivita, E
    Colabufo, NA
    Berardi, F
    Perrone, R
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (02) : 209 - 218
  • [8] Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs
    Sukalovic, V
    Andric, D
    Roglic, G
    Kostic-Rajacic, S
    Schrattenholz, A
    Soskic, V
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (05) : 481 - 493
  • [9] First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]-arylcarboxamide structure
    Leopoldo, M
    Lacivita, E
    Colabufo, NA
    Contino, M
    Berardi, F
    Perrone, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (25) : 7919 - 7922
  • [10] 4-[ω-[4-arylpiperazin-1-yl]alkoxy]phenylimidazo[1,2-a]pyridine derivatives:: fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualization
    Leopoldo, Marcello
    Lacivita, Enza
    Passafiume, Elena
    Contino, Marialessandra
    Colabufo, Nicola A.
    Berardi, Francesco
    Perrone, Roberto
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (20) : 5043 - 5047